ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
Get Alerts EPIX Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time.
David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.
A live webcast of the Oppenheimer presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-at-the-oppenheimer-33rd-annual-healthcare-conference-301765119.html
SOURCE ESSA Pharma Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acer Launches New Aspire Devices for Creators, Gamers, and Families
- KuCoin Web3 Wallet Advances Onchain Execution with Expanded Swap Routes and Limit Orders
- Operation Homefront Opens Nominations for 19th Annual Military Child of the Year® Award Honoring America's Military Children
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share